Raphael_2025_Cochrane.Database.Syst.Rev_11_Cd016310

Reference

Title : Sugammadex for reversing neuromuscular blockade in infants and children - Raphael_2025_Cochrane.Database.Syst.Rev_11_Cd016310
Author(s) : Raphael CK , El Bcherawi N , Atallah F , Moukarzel M , Kassab N , HajAli T , Rizk L , Dagher R , Khabsa J , Aouad-Maroun M
Ref : Cochrane Database Syst Rev , 11 :Cd016310 , 2025
Abstract :

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: The primary objective of this review is to evaluate the benefits and harms of sugammadex compared to other neuromuscular blockade reversal agents (neostigmine and pyridostigmine) in infants and children undergoing surgical procedures. A secondary objective is to assess whether these outcomes differ by age group, comorbidities, co-medications, or type of neuromuscular blocking agent.

PubMedSearch : Raphael_2025_Cochrane.Database.Syst.Rev_11_Cd016310
PubMedID: 41257414

Related information

Citations formats

Raphael CK, El Bcherawi N, Atallah F, Moukarzel M, Kassab N, HajAli T, Rizk L, Dagher R, Khabsa J, Aouad-Maroun M (2025)
Sugammadex for reversing neuromuscular blockade in infants and children
Cochrane Database Syst Rev 11 :Cd016310

Raphael CK, El Bcherawi N, Atallah F, Moukarzel M, Kassab N, HajAli T, Rizk L, Dagher R, Khabsa J, Aouad-Maroun M (2025)
Cochrane Database Syst Rev 11 :Cd016310